AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9628207 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong Yangsheng
Number of subjects: 30
Study 7942652 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide home bleaching agent for 72 hours before bonding
Number of subjects: 60
Study 7942652 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water immersion for 1 week after bleaching for 72 hours
Number of subjects: 60
Study 7942652 — intervention group
Group type: COMPARATOR
Intervention: Control group (etched and bonded in the usual manner)
Number of subjects: 60
Study 3069752 — intervention group
Group type: EXPERIMENTAL
Intervention: SR‐Nic (slow-release nicardipine)
Number of subjects: 30
Study 3069752 — intervention group
Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 30
Study 31223042 — intervention group
Group type: EXPERIMENTAL
Intervention: 19.5 mg LNG-IUS
Number of subjects: 1697
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: Women born between 1925 and 1929
Number of subjects: 202638
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: Women born between 1950 and 1955
Number of subjects: 202638
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger birth cohorts (born between 1935 and 1955)
Number of subjects: 202638
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: Women born between 1925 and 1945
Number of subjects: 202638
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent cohorts after 1945
Number of subjects: 202638
Study 28264823 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 202638
Study 26206385 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for specialists (14 hours, with 2.5 hours focused on reply letters)
Number of subjects: 123
Study 26206385 — intervention group
Group type: COMPARATOR
Intervention: Untrained doctors
Number of subjects: 123
Study 24130343 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster-enhanced preconception counseling (READY-Girls) program
Number of subjects: 109
Study 24130343 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group (CG)
Number of subjects: 109
Study 21417809 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Qigong (HQG) intervention group, n = 40
Number of subjects: 80
Study 21417809 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 40
Number of subjects: 80
Study 18490865 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard vaginal gel
Number of subjects: 55
Study 18490865 — intervention group
Group type: COMPARATOR
Intervention: Methyl-cellulose placebo gel
Number of subjects: 55
Study 17310818 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-containing regimens
Number of subjects: 3314
Study 12690904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g orally)
Number of subjects: 11
Study 12690904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11006366 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan, fluorouracil, and leucovorin
Number of subjects: 683
Study 11006366 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 683
Study 8780533 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1027
Study 1514349 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (6 micrograms.kg‐1)
Number of subjects: 48
Study 1514349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6735736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense intervention
Number of subjects: 0
Study 6735736 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0
Study 6735736 — intervention group
Group type: COMPARATOR
Intervention: Simple feedback of performance measures
Number of subjects: 0
Study 6735736 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoercive methods involving health care providers
Number of subjects: 0
Study 30670043 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tool and order set embedded in the EHR.
Number of subjects: 10939
Study 30670043 — intervention group
Group type: COMPARATOR
Intervention: Control group with no alert for tobacco treatment.
Number of subjects: 10939
Study 30577513 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐Eudesmol beverage
Number of subjects: 50
Study 30577513 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 50
Study 27614402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 10
Study 27614402 — intervention group
Group type: COMPARATOR
Intervention: Dual tDCS
Number of subjects: 10
Study 24835753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 39
Study 24835753 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard balance training
Number of subjects: 39
Study 24835753 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 39
Study 24835753 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 39
Study 22973819 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-behavioural intervention
Number of subjects: 2070
Study 20651593 — intervention group
Group type: EXPERIMENTAL
Intervention: External dacryocystorhinostomy
Number of subjects: 0
Study 20651593 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal dacryocystorhinostomy
Number of subjects: 0
Study 20651593 — intervention group
Group type: COMPARATOR
Intervention: Comparison of external and endonasal dacryocystorhinostomy
Number of subjects: 0
Study 18720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 6 mg/day infused separately
Number of subjects: 10
Study 18720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 6 mg/day added to TPN
Number of subjects: 10
Study 18720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum level
Number of subjects: 10
Study 18720937 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment serum level
Number of subjects: 10
Study 15989121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 72
Study 15989121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Interview (CI)
Number of subjects: 72
Study 15989121 — intervention group
Group type: COMPARATOR
Intervention: Motivated, Repeated Recall (MRR)
Number of subjects: 72
Study 15989121 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Interrogatory Recall Test (all conditions)
Number of subjects: 72
Study 15989121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP) and Cognitive Interview (CI)
Number of subjects: 72
Study 12447222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophy cup with fine flour pumice
Number of subjects: 22
Study 12447222 — intervention group
Group type: COMPARATOR
Intervention: No. 23 dental explorer and air-water spray
Number of subjects: 22
Study 12447222 — intervention group
Group type: COMPARATOR
Intervention: Cotton pellet soaked in chlorhexidine gluconate, 0.12%
Number of subjects: 22
Study 10955129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg as a first oral dose followed after 8 hrs by 150 mg (Group A)
Number of subjects: 188
Study 10955129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg as a first dose, followed by the same dose 3 and again 8 hrs later (Group B)
Number of subjects: 188
Study 10955129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg every 3 hrs, up to a total dose of 600 mg (Group C)
Number of subjects: 188
Study 8551493 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol therapy
Number of subjects: 22
Study 8551493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2182746 — intervention group
Group type: EXPERIMENTAL
Intervention: local hyperthermia combined with radiation
Number of subjects: 25
Study 2182746 — intervention group
Group type: COMPARATOR
Intervention: radiation alone
Number of subjects: 25
Study 23495 — intervention group
Group type: EXPERIMENTAL
Intervention: New-health-practitioner protocol system
Number of subjects: 472
Study 23495 — intervention group
Group type: COMPARATOR
Intervention: Physician-only nonprotocol system
Number of subjects: 472
Study 31113453 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic management support programme to increase innovation leadership skills
Number of subjects: 8
Study 31113453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention initially)
Number of subjects: 8
Study 29017497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (DPP-4 inhibitor) add-on group
Number of subjects: 97
Study 29017497 — intervention group
Group type: COMPARATOR
Intervention: High-dose metformin (double dose)
Number of subjects: 97
Study 25624432 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone
Number of subjects: 1088
Study 25624432 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 1088
Study 23812010 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with Trabectome
Number of subjects: 55
Study 23812010 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification combined with trabecular aspiration
Number of subjects: 55
Study 21910074 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis combined with hydroxychloroquine sulfate tablet (HCQ) for 3 months
Number of subjects: 68
Study 21910074 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate tablet (HCQ) only for 3 months
Number of subjects: 68
Study 18199279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride
Number of subjects: 0
Study 16624227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined maintenance ECT plus nortriptyline
Number of subjects: 19
Study 16624227 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 19
Study 12879732 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy plus manual lymph drainage
Number of subjects: 23
Study 12879732 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (control)
Number of subjects: 23
Study 11079363 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 200 mg/day
Number of subjects: 34
Study 11079363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1618631 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Social Learning Theory (HBM‐SLT) program
Number of subjects: 1444
Study 1618631 — intervention group
Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 1444
Study 6328288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding with adequate vitamin D and phosphate supplementation
Number of subjects: 0
Study 6328288 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding with vitamin D supplementation
Number of subjects: 0
Study 31018614 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT with beer (T-Beer group)
Number of subjects: 72
Study 31018614 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT with alcohol equivalent (T-Ethanol group)
Number of subjects: 72
Study 31018614 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT with alcohol-free beer (T-0.0Beer group)
Number of subjects: 72
Study 31018614 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT with sparkling water (T-Water group)
Number of subjects: 72
Study 31018614 — intervention group
Group type: COMPARATOR
Intervention: Non-Training group
Number of subjects: 72
Study 29771313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25862567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 346
Study 25862567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel
Number of subjects: 346
Study 24691218 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (12 weeks, twice per week)
Number of subjects: 30
Study 24691218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study 22015737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine 8 mg lozenge
Number of subjects: 165
Study 22015737 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 165
Study 20039221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg . kg(‐1)
Number of subjects: 75
Study 20039221 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg . kg(‐1)
Number of subjects: 75
Study 20039221 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 75
Study 17593871 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy with preservation of both ovaries
Number of subjects: 29
Study 17593871 — intervention group
Group type: COMPARATOR
Intervention: Control group (menopausal patients with no previous ovarian pathology)
Number of subjects: 29
Study 16037703 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5‐Fr catheter and 6‐Fr catheter (Group A)
Number of subjects: 60
Study 16037703 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5‐Fr catheter and 7‐Fr catheter (Group B)
Number of subjects: 60
Study 16037703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-flow studies
Number of subjects: 60
Study 16037703 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusor pressure at maximum flow (Pdet. Qmax) and maximum detrusor pressure (P(det. max))
Number of subjects: 60
Study 12100764 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol metered-dose inhaler (MDI) 1.2 mg
Number of subjects: 10
Study 12100764 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of salbutamol 1.2 mg
Number of subjects: 10
Study 10450579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap
Number of subjects: 117
Study 10450579 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap
Number of subjects: 117
Study 10450579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled transverse rectus abdominis muscle flap
Number of subjects: 117
Study 10450579 — intervention group
Group type: COMPARATOR
Intervention: Reference group (30 patients followed up outside the randomised study)
Number of subjects: 117
Study 8767529 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan/prednisone (MP) as first-line treatment in 84 patients (74%)
Number of subjects: 113
Study 8767529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stage I-II disease
Number of subjects: 113
Study 8767529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stage III disease
Number of subjects: 113
Study 8767529 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive disease
Number of subjects: 113
Study 8767529 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory disease
Number of subjects: 113
Study 1858732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice flour solution
Number of subjects: 66
Study 1858732 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization rehydration solution by gastric infusion
Number of subjects: 66
Study 1858732 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization rehydration solution orally
Number of subjects: 66
Study 6621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Thomsen-Friedenreich (T) antigen skin test
Number of subjects: 40
Study 6621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) blood levels
Number of subjects: 40
Study 31514186 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased antiphosphatidylserine antibodies (aPS) in patients with abnormal renal function
Number of subjects: 2874
Study 31514186 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased antiphosphatidylserine antibodies (aPS) in patients with normal renal function
Number of subjects: 2874
Study 31514186 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of aPS levels in patients with abnormal renal function
Number of subjects: 2874
Study 31514186 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of aPS levels in patients with normal renal function
Number of subjects: 2874
Study 28297827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside ultrasound monitoring of gastric residual volume every day
Number of subjects: 70
Study 28297827 — intervention group
Group type: COMPARATOR
Intervention: Syringes withdrawing every 8 hours to measure gastric residual volume
Number of subjects: 70
Study 26806045 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g/d)
Number of subjects: 240
Study 26806045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-fat spreads without added PS)
Number of subjects: 240
Study 24886151 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported cognitive behavioral therapy self-help (CBTsh) supported by mental health paraprofessionals
Number of subjects: 0
Study 24886151 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study 22424003 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine supplemental oxygen therapy
Number of subjects: 490
Study 22424003 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 490
Study 19802030 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0
Study 19802030 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 17931241 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant (10 cm x 10 cm)
Number of subjects: 557
Study 17931241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gentamicin-collagen implant)
Number of subjects: 557
Study 16219105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine infusions weekly over 4 weeks.
Number of subjects: 66
Study 16219105 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks.
Number of subjects: 66
Study 11914401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 50
Study 11914401 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 50
Study 9872641 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 10
Study 9872641 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Number of subjects: 10
Study 9872641 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% Helium in 30% Oxygen
Number of subjects: 10
Study 9872641 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% Nitrous Oxide in 30% Oxygen
Number of subjects: 10
Study 7613835 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior bladder neck tube reconstruction
Number of subjects: 17
Study 7613835 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior 'racket handle' closures
Number of subjects: 17
Study 1958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Agoraphobia
Number of subjects: 1168
Study 1958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness phobia
Number of subjects: 1168
Study 1958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobia
Number of subjects: 1168
Study 1958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of open spaces
Number of subjects: 1168
Study 1958949 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of panic attacks
Number of subjects: 1168
Study 7318340 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (2.25 mmol of Na+/kg) over 30 min
Number of subjects: 0
Study 7318340 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sodium loading
Number of subjects: 0
Study 7318340 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sodium load
Number of subjects: 0
Study 7318340 — intervention group
Group type: COMPARATOR
Intervention: Posture effect
Number of subjects: 0
Study 7318340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium effect on cell sodium transport
Number of subjects: 0
Study 30884006 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 seconds additional ablation duration
Number of subjects: 75
Study 30884006 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 seconds additional ablation duration
Number of subjects: 75
Study 30884006 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 seconds additional ablation duration
Number of subjects: 75
Study 29096689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered indomethacin
Number of subjects: 1370
Study 29096689 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1370
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 12 weeks
Number of subjects: 377
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 12 weeks
Number of subjects: 377
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg plus ribavirin for 8 weeks
Number of subjects: 377
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 8 weeks
Number of subjects: 377
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 100 mg plus ribavirin for 8 weeks
Number of subjects: 377
Study 26551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 8 weeks
Number of subjects: 377
Study 24169421 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent documents (ICDs) with varying control over breadth of release of genetic information
Number of subjects: 229
Study 24169421 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent documents (ICDs)
Number of subjects: 229
Study 21537591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensi Kill
Number of subjects: 13
Study 21537591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxa-Gel
Number of subjects: 13